Click here to get full coverage on CG Oncology, Inc. (NASDAQ:CGON) Sees Large Decline in Short Interest - MarketBeat

CG Oncology, Inc. (NASDAQ:CGON) Sees Large Decline in Short Interest  MarketBeat

CG Oncology, Inc. (NASDAQ:CGON) Sees Large Decline in Short Interest - MarketBeat

Click here to get full coverage on Is BOND-003’s Phase 3 Progress Reshaping The Investment Case For CG Oncology (CGON)? - simplywall.st

Is BOND-003’s Phase 3 Progress Reshaping The Investment Case For CG Oncology (CGON)?  simplywall.st

Is BOND-003’s Phase 3 Progress Reshaping The Investment Case For CG Oncology (CGON)? - simplywall.st

Click here to get full coverage on Is CG Oncology (CGON) Stock Pricing In Its Recent 79% One Year Surge? - Yahoo Finance

Is CG Oncology (CGON) Stock Pricing In Its Recent 79% One Year Surge?  Yahoo Finance

Is CG Oncology (CGON) Stock Pricing In Its Recent 79% One Year Surge? - Yahoo Finance

Click here to get full coverage on CG Oncology, Inc. (CGON) Stock Analysis: A Biotech Gem With 48.62% Upside Potential - DirectorsTalk Interviews

CG Oncology, Inc. (CGON) Stock Analysis: A Biotech Gem With 48.62% Upside Potential  DirectorsTalk Interviews

CG Oncology, Inc. (CGON) Stock Analysis: A Biotech Gem With 48.62% Upside Potential - DirectorsTalk Interviews

Click here to get full coverage on CG Oncology: 'Strong Buy' On Earlier Than Expected Completed Recruitment Cretostimogene - Seeking Alpha

CG Oncology: 'Strong Buy' On Earlier Than Expected Completed Recruitment Cretostimogene  Seeking Alpha

CG Oncology: 'Strong Buy' On Earlier Than Expected Completed Recruitment Cretostimogene - Seeking Alpha

Click here to get full coverage on CG Oncology Stock Rallies Nearly 32% in a Week: Here is Why - Zacks Investment Research

CG Oncology Stock Rallies Nearly 32% in a Week: Here is Why  Zacks Investment Research

CG Oncology Stock Rallies Nearly 32% in a Week: Here is Why - Zacks Investment Research

Click here to get full coverage on CG Oncology (NASDAQ: CGON) highlights BOND-003 and CORE-008 NMIBC data at SUO meeting - Stock Titan

CG Oncology (NASDAQ: CGON) highlights BOND-003 and CORE-008 NMIBC data at SUO meeting  Stock Titan

CG Oncology (NASDAQ: CGON) highlights BOND-003 and CORE-008 NMIBC data at SUO meeting - Stock Titan

Click here to get full coverage on CG Oncology (CGON) Is Up 29.7% After Accelerating PIVOT-006 Phase 3 Timeline - Has The Bull Case Changed? - Yahoo Finance

CG Oncology (CGON) Is Up 29.7% After Accelerating PIVOT-006 Phase 3 Timeline - Has The Bull Case Changed?  Yahoo Finance

CG Oncology (CGON) Is Up 29.7% After Accelerating PIVOT-006 Phase 3 Timeline - Has The Bull Case Changed? - Yahoo Finance

Click here to get full coverage on Assessing CG Oncology (CGON) Valuation After Accelerated PIVOT-006 Phase 3 Trial Timeline - simplywall.st

Assessing CG Oncology (CGON) Valuation After Accelerated PIVOT-006 Phase 3 Trial Timeline  simplywall.st

Assessing CG Oncology (CGON) Valuation After Accelerated PIVOT-006 Phase 3 Trial Timeline - simplywall.st

Click here to get full coverage on CG Oncology, Inc. (CGON) is a Buy on Cancer Treatment Development: Truist Securities - Yahoo Finance

CG Oncology, Inc. (CGON) is a Buy on Cancer Treatment Development: Truist Securities  Yahoo Finance

CG Oncology, Inc. (CGON) is a Buy on Cancer Treatment Development: Truist Securities - Yahoo Finance

Click here to get full coverage on CG Oncology, Inc. (CGON) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance

CG Oncology, Inc. (CGON) Reports Q3 Loss, Tops Revenue Estimates  Yahoo Finance

CG Oncology, Inc. (CGON) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance

Click here to get full coverage on CG Oncology (CGON): Assessing Valuation Following Analyst Coverage and Positive Phase 3 Trial Results - Yahoo Finance

CG Oncology (CGON): Assessing Valuation Following Analyst Coverage and Positive Phase 3 Trial Results  Yahoo Finance

CG Oncology (CGON): Assessing Valuation Following Analyst Coverage and Positive Phase 3 Trial Results - Yahoo Finance

Click here to get full coverage on How Positive Cretostimogene Trial Updates And Leadership Moves At CG Oncology (CGON) Have Changed Its Investment Story - Yahoo Finance

How Positive Cretostimogene Trial Updates And Leadership Moves At CG Oncology (CGON) Have Changed Its Investment Story  Yahoo Finance

How Positive Cretostimogene Trial Updates And Leadership Moves At CG Oncology (CGON) Have Changed Its Investment Story - Yahoo Finance

Click here to get full coverage on What CG Oncology (CGON)'s FDA BLA Submission and Phase 3 Progress Mean for Shareholders - Yahoo Finance

What CG Oncology (CGON)'s FDA BLA Submission and Phase 3 Progress Mean for Shareholders  Yahoo Finance

What CG Oncology (CGON)'s FDA BLA Submission and Phase 3 Progress Mean for Shareholders - Yahoo Finance

Click here to get full coverage on Guggenheim Initiates CG Oncology (CGON) Coverage with $90 PT, Highlights Bladder Cancer Therapeutic Cretostimogene - Yahoo Finance

Guggenheim Initiates CG Oncology (CGON) Coverage with $90 PT, Highlights Bladder Cancer Therapeutic Cretostimogene  Yahoo Finance

Guggenheim Initiates CG Oncology (CGON) Coverage with $90 PT, Highlights Bladder Cancer Therapeutic Cretostimogene - Yahoo Finance

Click here to get full coverage on CG Oncology (CGON) Is Up 23.3% After 24-Month Complete Response Data in Phase 3 Bladder Cancer Study - Yahoo Finance

CG Oncology (CGON) Is Up 23.3% After 24-Month Complete Response Data in Phase 3 Bladder Cancer Study  Yahoo Finance

CG Oncology (CGON) Is Up 23.3% After 24-Month Complete Response Data in Phase 3 Bladder Cancer Study - Yahoo Finance

Click here to get full coverage on CG Oncology (CGON) Gets Initiated With a Buy at Guggenheim - Yahoo Finance

CG Oncology (CGON) Gets Initiated With a Buy at Guggenheim  Yahoo Finance

CG Oncology (CGON) Gets Initiated With a Buy at Guggenheim - Yahoo Finance

Click here to get full coverage on CG Oncology (CGON) PT Raised to $79 by Morgan Stanley on Strong Clinical Pipeline for Bladder Cancer Treatment - Yahoo Finance

CG Oncology (CGON) PT Raised to $79 by Morgan Stanley on Strong Clinical Pipeline for Bladder Cancer Treatment  Yahoo Finance

CG Oncology (CGON) PT Raised to $79 by Morgan Stanley on Strong Clinical Pipeline for Bladder Cancer Treatment - Yahoo Finance

Click here to get full coverage on CG Oncology, Inc. (CGON) Moves 5.5% Higher: Will This Strength Last? - Yahoo Finance

CG Oncology, Inc. (CGON) Moves 5.5% Higher: Will This Strength Last?  Yahoo Finance

CG Oncology, Inc. (CGON) Moves 5.5% Higher: Will This Strength Last? - Yahoo Finance

Click here to get full coverage on CG Oncology, Inc. (CGON) Reports 75.5% Complete Response in Bladder Cancer Trial - Yahoo Finance

CG Oncology, Inc. (CGON) Reports 75.5% Complete Response in Bladder Cancer Trial  Yahoo Finance

CG Oncology, Inc. (CGON) Reports 75.5% Complete Response in Bladder Cancer Trial - Yahoo Finance

Click here to get full coverage on CG Oncology (NASDAQ:CGON) Sets New 52-Week High - Should You Buy? - MarketBeat

CG Oncology (NASDAQ:CGON) Sets New 52-Week High - Should You Buy?  MarketBeat

CG Oncology (NASDAQ:CGON) Sets New 52-Week High - Should You Buy? - MarketBeat

Click here to get full coverage on What Analysts Are Saying About CG Oncology Stock - Benzinga

What Analysts Are Saying About CG Oncology Stock  Benzinga

What Analysts Are Saying About CG Oncology Stock - Benzinga

Click here to get full coverage on CGON: RBC Capital Raises Price Target to $73, Maintains Outperfo - GuruFocus

CGON: RBC Capital Raises Price Target to $73, Maintains Outperfo  GuruFocus

CGON: RBC Capital Raises Price Target to $73, Maintains Outperfo - GuruFocus

Click here to get full coverage on Assessing CG Oncology (CGON) Valuation After Accelerated PIVOT-006 Phase 3 Trial Timeline - Sahm

Assessing CG Oncology (CGON) Valuation After Accelerated PIVOT-006 Phase 3 Trial Timeline  Sahm

Assessing CG Oncology (CGON) Valuation After Accelerated PIVOT-006 Phase 3 Trial Timeline - Sahm

Click here to get full coverage on James Mulay Sells 11,145 Shares of CG Oncology (NASDAQ:CGON) Stock - MarketBeat

James Mulay Sells 11,145 Shares of CG Oncology (NASDAQ:CGON) Stock  MarketBeat

James Mulay Sells 11,145 Shares of CG Oncology (NASDAQ:CGON) Stock - MarketBeat

Click here to get full coverage on $CGON stock is up 30% today. Here's what we see in our data. - Quiver Quantitative

$CGON stock is up 30% today. Here's what we see in our data.  Quiver Quantitative

$CGON stock is up 30% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on H.C. Wainwright Reiterates a Buy on CG Oncology (CGON), Keeps the PT - Yahoo Finance

H.C. Wainwright Reiterates a Buy on CG Oncology (CGON), Keeps the PT  Yahoo Finance

H.C. Wainwright Reiterates a Buy on CG Oncology (CGON), Keeps the PT - Yahoo Finance

Click here to get full coverage on CG Oncology Undervalued Going Into A Busy 2026 (NASDAQ:CGON) - Seeking Alpha

CG Oncology Undervalued Going Into A Busy 2026 (NASDAQ:CGON)  Seeking Alpha

CG Oncology Undervalued Going Into A Busy 2026 (NASDAQ:CGON) - Seeking Alpha

Click here to get full coverage on Bladder cancer trial to deliver key results nearly a year early - Stock Titan

Bladder cancer trial to deliver key results nearly a year early  Stock Titan

Bladder cancer trial to deliver key results nearly a year early - Stock Titan

Click here to get full coverage on CG Oncology, Inc. (CGON) Stock Analysis: A Biotech Powerhouse with 41.87% Potential Upside - DirectorsTalk Interviews

CG Oncology, Inc. (CGON) Stock Analysis: A Biotech Powerhouse with 41.87% Potential Upside  DirectorsTalk Interviews

CG Oncology, Inc. (CGON) Stock Analysis: A Biotech Powerhouse with 41.87% Potential Upside - DirectorsTalk Interviews

Click here to get full coverage on CG Oncology stock initiated Buy at Guggenheim (CGON:NASDAQ) - Seeking Alpha

CG Oncology stock initiated Buy at Guggenheim (CGON:NASDAQ)  Seeking Alpha

CG Oncology stock initiated Buy at Guggenheim (CGON:NASDAQ) - Seeking Alpha

Click here to get full coverage on CG Oncology: Upgraded, Rising, But Should We Still Be Optimistic? (NASDAQ:CGON) - Seeking Alpha

CG Oncology: Upgraded, Rising, But Should We Still Be Optimistic? (NASDAQ:CGON)  Seeking Alpha

CG Oncology: Upgraded, Rising, But Should We Still Be Optimistic? (NASDAQ:CGON) - Seeking Alpha

Click here to get full coverage on Assessing CG Oncology (CGON) Valuation After Strong Recent Share Price Momentum - Sahm

Assessing CG Oncology (CGON) Valuation After Strong Recent Share Price Momentum  Sahm

Assessing CG Oncology (CGON) Valuation After Strong Recent Share Price Momentum - Sahm

Click here to get full coverage on $CGON stock is up 10% today. Here's what we see in our data. - Quiver Quantitative

$CGON stock is up 10% today. Here's what we see in our data.  Quiver Quantitative

$CGON stock is up 10% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on CG Oncology stock soars after Phase 3 trial data timeline accelerated - Investing.com

CG Oncology stock soars after Phase 3 trial data timeline accelerated  Investing.com

CG Oncology stock soars after Phase 3 trial data timeline accelerated - Investing.com

Click here to get full coverage on Liu Brian Guan-Chyun buys CG Oncology (CGON) shares worth $49.9m - Investing.com

Liu Brian Guan-Chyun buys CG Oncology (CGON) shares worth $49.9m  Investing.com

Liu Brian Guan-Chyun buys CG Oncology (CGON) shares worth $49.9m - Investing.com

Click here to get full coverage on Why CG Oncology, Inc. (CGON) Surged on Monday - Yahoo Finance

Why CG Oncology, Inc. (CGON) Surged on Monday  Yahoo Finance

Why CG Oncology, Inc. (CGON) Surged on Monday - Yahoo Finance

Click here to get full coverage on Precision Trading with CGON Inc (CGON) Risk Zones - Stock Traders Daily

Precision Trading with CGON Inc (CGON) Risk Zones  Stock Traders Daily

Precision Trading with CGON Inc (CGON) Risk Zones - Stock Traders Daily

Click here to get full coverage on CG Oncology, Inc. (CGON) Has a New Rating from Truist Financial - The Globe and Mail

CG Oncology, Inc. (CGON) Has a New Rating from Truist Financial  The Globe and Mail

CG Oncology, Inc. (CGON) Has a New Rating from Truist Financial - The Globe and Mail

Click here to get full coverage on Insider Purchase: Director at $CGON Buys 1,515,151 Shares - Quiver Quantitative

Insider Purchase: Director at $CGON Buys 1,515,151 Shares  Quiver Quantitative

Insider Purchase: Director at $CGON Buys 1,515,151 Shares - Quiver Quantitative

Click here to get full coverage on Is Accelerated PIVOT-006 Data for Cretostimogene Reshaping the Investment Case for CG Oncology (CGON)? - simplywall.st

Is Accelerated PIVOT-006 Data for Cretostimogene Reshaping the Investment Case for CG Oncology (CGON)?  simplywall.st

Is Accelerated PIVOT-006 Data for Cretostimogene Reshaping the Investment Case for CG Oncology (CGON)? - simplywall.st

Click here to get full coverage on Dip Buying: Can CGON deliver alpha - 2025 Analyst Calls & Long-Term Growth Stock Strategies - baoquankhu1.vn

Dip Buying: Can CGON deliver alpha - 2025 Analyst Calls & Long-Term Growth Stock Strategies  baoquankhu1.vn

Dip Buying: Can CGON deliver alpha - 2025 Analyst Calls & Long-Term Growth Stock Strategies - baoquankhu1.vn

Click here to get full coverage on CG Oncology Announces Participation in 44th Annual J.P. Morgan Healthcare Conference - Quiver Quantitative

CG Oncology Announces Participation in 44th Annual J.P. Morgan Healthcare Conference  Quiver Quantitative

CG Oncology Announces Participation in 44th Annual J.P. Morgan Healthcare Conference - Quiver Quantitative

Click here to get full coverage on CG Oncology, Inc. (NASDAQ:CGON) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat

CG Oncology, Inc. (NASDAQ:CGON) Given Consensus Rating of "Moderate Buy" by Brokerages  MarketBeat

CG Oncology, Inc. (NASDAQ:CGON) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat

Click here to get full coverage on CG Oncology (NASDAQ:CGON) Sets New 52-Week High - Time to Buy? - MarketBeat

CG Oncology (NASDAQ:CGON) Sets New 52-Week High - Time to Buy?  MarketBeat

CG Oncology (NASDAQ:CGON) Sets New 52-Week High - Time to Buy? - MarketBeat

Click here to get full coverage on After-Hours Rally Lifts PALI, HCTI, NTRB, KPTI, EDIT, And CGON On Mixed News And Strategic Moves - Nasdaq

After-Hours Rally Lifts PALI, HCTI, NTRB, KPTI, EDIT, And CGON On Mixed News And Strategic Moves  Nasdaq

After-Hours Rally Lifts PALI, HCTI, NTRB, KPTI, EDIT, And CGON On Mixed News And Strategic Moves - Nasdaq

Click here to get full coverage on CG Oncology (CGON): Assessing Valuation Following Landmark 24-Month BOND-003 Results for Bladder Cancer Therapy - simplywall.st

CG Oncology (CGON): Assessing Valuation Following Landmark 24-Month BOND-003 Results for Bladder Cancer Therapy  simplywall.st

CG Oncology (CGON): Assessing Valuation Following Landmark 24-Month BOND-003 Results for Bladder Cancer Therapy - simplywall.st

Click here to get full coverage on Cgon stock hits 52-week high at 40.67 USD - Investing.com

Cgon stock hits 52-week high at 40.67 USD  Investing.com

Cgon stock hits 52-week high at 40.67 USD - Investing.com

Click here to get full coverage on New Analyst Forecast: $CGON Given $61.0 Price Target - Quiver Quantitative

New Analyst Forecast: $CGON Given $61.0 Price Target  Quiver Quantitative

New Analyst Forecast: $CGON Given $61.0 Price Target - Quiver Quantitative

Click here to get full coverage on Why Cg Oncology Stock Rocketed 7% Higher Today - The Motley Fool

Why Cg Oncology Stock Rocketed 7% Higher Today  The Motley Fool

Why Cg Oncology Stock Rocketed 7% Higher Today - The Motley Fool

Click here to get full coverage on CG Oncology rises after expediting a late-stage trial readout for lead asset - Seeking Alpha

CG Oncology rises after expediting a late-stage trial readout for lead asset  Seeking Alpha

CG Oncology rises after expediting a late-stage trial readout for lead asset - Seeking Alpha

Click here to get full coverage on Is Accelerated PIVOT-006 Data for Cretostimogene Reshaping the Investment Case for CG Oncology (CGON)? - Sahm

Is Accelerated PIVOT-006 Data for Cretostimogene Reshaping the Investment Case for CG Oncology (CGON)?  Sahm

Is Accelerated PIVOT-006 Data for Cretostimogene Reshaping the Investment Case for CG Oncology (CGON)? - Sahm

Click here to get full coverage on CG Oncology: Looking Undervalued Heading Toward FDA Submission (Upgrade) (NASDAQ:CGON) - Seeking Alpha

CG Oncology: Looking Undervalued Heading Toward FDA Submission (Upgrade) (NASDAQ:CGON)  Seeking Alpha

CG Oncology: Looking Undervalued Heading Toward FDA Submission (Upgrade) (NASDAQ:CGON) - Seeking Alpha

Click here to get full coverage on How CGON stock trades before earnings - July 2025 Rallies & Entry Point Strategy Guides - mfd.ru

How CGON stock trades before earnings - July 2025 Rallies & Entry Point Strategy Guides  mfd.ru

How CGON stock trades before earnings - July 2025 Rallies & Entry Point Strategy Guides - mfd.ru

Click here to get full coverage on Cgon stock hits 52-week high at 45.98 USD - Investing.com

Cgon stock hits 52-week high at 45.98 USD  Investing.com

Cgon stock hits 52-week high at 45.98 USD - Investing.com

Click here to get full coverage on CG Oncology Announces Expedited Timeline for Phase 3 PIVOT-006 Trial Data on Cretostimogene for Intermediate-Risk NMIBC - Quiver Quantitative

CG Oncology Announces Expedited Timeline for Phase 3 PIVOT-006 Trial Data on Cretostimogene for Intermediate-Risk NMIBC  Quiver Quantitative

CG Oncology Announces Expedited Timeline for Phase 3 PIVOT-006 Trial Data on Cretostimogene for Intermediate-Risk NMIBC - Quiver Quantitative

Click here to get full coverage on CG Oncology (NASDAQ:CGON) Shares Down 6.3% - Here's What Happened - MarketBeat

CG Oncology (NASDAQ:CGON) Shares Down 6.3% - Here's What Happened  MarketBeat

CG Oncology (NASDAQ:CGON) Shares Down 6.3% - Here's What Happened - MarketBeat

Click here to get full coverage on CG Oncology Stock Rallies Nearly 32% in a Week: Here is Why - Eastern Progress

CG Oncology Stock Rallies Nearly 32% in a Week: Here is Why  Eastern Progress

CG Oncology Stock Rallies Nearly 32% in a Week: Here is Why - Eastern Progress

Click here to get full coverage on Mulay, James sells CG Oncology (CGON) shares for $584,798 By Investing.com - Investing.com Nigeria

Mulay, James sells CG Oncology (CGON) shares for $584,798 By Investing.com  Investing.com Nigeria

Mulay, James sells CG Oncology (CGON) shares for $584,798 By Investing.com - Investing.com Nigeria

Click here to get full coverage on CG Oncology Gains Momentum as Price Targets and Investor Confidence Rise - StocksToTrade

CG Oncology Gains Momentum as Price Targets and Investor Confidence Rise  StocksToTrade

CG Oncology Gains Momentum as Price Targets and Investor Confidence Rise - StocksToTrade

Click here to get full coverage on BofA Securities Maintains CG Oncology(CGON.US) With Buy Rating, Raises Target Price to $65 - 富途牛牛

BofA Securities Maintains CG Oncology(CGON.US) With Buy Rating, Raises Target Price to $65  富途牛牛

BofA Securities Maintains CG Oncology(CGON.US) With Buy Rating, Raises Target Price to $65 - 富途牛牛

Click here to get full coverage on Technical Reactions to CGON Trends in Macro Strategies - Stock Traders Daily

Technical Reactions to CGON Trends in Macro Strategies  Stock Traders Daily

Technical Reactions to CGON Trends in Macro Strategies - Stock Traders Daily

Click here to get full coverage on CG Oncology Stock Rallies Nearly 32% in a Week: Here is Why - The Globe and Mail

CG Oncology Stock Rallies Nearly 32% in a Week: Here is Why  The Globe and Mail

CG Oncology Stock Rallies Nearly 32% in a Week: Here is Why - The Globe and Mail

Click here to get full coverage on We're Not Very Worried About CG Oncology's (NASDAQ:CGON) Cash Burn Rate - simplywall.st

We're Not Very Worried About CG Oncology's (NASDAQ:CGON) Cash Burn Rate  simplywall.st

We're Not Very Worried About CG Oncology's (NASDAQ:CGON) Cash Burn Rate - simplywall.st

Click here to get full coverage on CG Oncology Accelerates Phase 3 Data Readout to First Half of 2026 - Intellectia AI

CG Oncology Accelerates Phase 3 Data Readout to First Half of 2026  Intellectia AI

CG Oncology Accelerates Phase 3 Data Readout to First Half of 2026 - Intellectia AI

Click here to get full coverage on Mulay, James sells CG Oncology (CGON) shares for $584,798 By Investing.com - Investing.com India

Mulay, James sells CG Oncology (CGON) shares for $584,798 By Investing.com  Investing.com India

Mulay, James sells CG Oncology (CGON) shares for $584,798 By Investing.com - Investing.com India

Click here to get full coverage on CG Oncology Files Amendment to Increase Stock Offering - TradingView

CG Oncology Files Amendment to Increase Stock Offering  TradingView

CGON

Price Chart

Key Statistics

Technicals

About CGON

Latest News

CG Oncology, Inc. (NASDAQ:CGON) Sees Large Decline in Short Interest - MarketBeat

Is BOND-003’s Phase 3 Progress Reshaping The Investment Case For CG Oncology (CGON)? - simplywall.st

Is CG Oncology (CGON) Stock Pricing In Its Recent 79% One Year Surge? - Yahoo Finance

Advanced Charts

Top Gainers

Top Losers